In Brief: Baxter/Corning Clinical Labs
This article was originally published in The Gray Sheet
Baxter/Corning Clinical Labs: Sign five-year sole-source distribution agreement for Baxter laboratory and diagnostic products which is expected to generate over $200 mil. in sales over the life of the deal. The agreement establishes a "collaborative partnership" between Baxter and CCL and emphasizes product standardization and reduced utilization to cut costs for CCL...
You may also be interested in...
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.